NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Orphazyme A/S (NASDAQ: ORPH)
ORPH Technical Analysis
5
As on 27th Apr 2022 ORPH STOCK Price closed @ 0.34 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 8.80 & Strong Sell for SHORT-TERM with Stoploss of 10.17 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ORPHSTOCK Price
Open | 0.30 | Change | Price | % |
High | 0.35 | 1 Day | 0.01 | 3.03 |
Low | 0.30 | 1 Week | -0.53 | -60.92 |
Close | 0.34 | 1 Month | -0.92 | -73.02 |
Volume | 38961 | 1 Year | -10.05 | -96.73 |
52 Week High 21.00 | 52 Week Low 0.32 |
NASDAQ USA Most Active Stocks
TSLA | 244.40 | 4.06% |
TTOO | 0.07 | -12.50% |
SOFI | 8.18 | 0.74% |
FFIE | 0.33 | 6.45% |
PONO | 1.72 | 2.38% |
AMD | 124.92 | 3.20% |
IDEX | 0.06 | 0.00% |
NKLA | 0.70 | 14.75% |
AMZN | 123.43 | -0.66% |
AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
ORPH Daily Charts |
ORPH Intraday Charts |
Whats New @ Bazaartrend |
ORPH Free Analysis |
|
ORPH Important Levels Intraday
RESISTANCE | 0.44 |
RESISTANCE | 0.41 |
RESISTANCE | 0.39 |
RESISTANCE | 0.37 |
SUPPORT | 0.31 |
SUPPORT | 0.29 |
SUPPORT | 0.27 |
SUPPORT | 0.24 |
ORPH Forecast May 2024
4th UP Forecast | 6.8 |
3rd UP Forecast | 4.73 |
2nd UP Forecast | 3.45 |
1st UP Forecast | 2.17 |
1st DOWN Forecast | -1.49 |
2nd DOWN Forecast | -2.77 |
3rd DOWN Forecast | -4.05 |
4th DOWN Forecast | -6.12 |
ORPH Weekly Forecast
4th UP Forecast | 2.09 |
3rd UP Forecast | 1.53 |
2nd UP Forecast | 1.18 |
1st UP Forecast | 0.84 |
1st DOWN Forecast | -0.16 |
2nd DOWN Forecast | -0.50 |
3rd DOWN Forecast | -0.85 |
4th DOWN Forecast | -1.41 |
ORPH Forecast2024
4th UP Forecast | 149.62 |
3rd UP Forecast | 101.75 |
2nd UP Forecast | 72.15 |
1st UP Forecast | 42.56 |
1st DOWN Forecast | -41.88 |
2nd DOWN Forecast | -71.47 |
3rd DOWN Forecast | -101.07 |
4th DOWN Forecast | -148.94 |
Orphazyme A/S ( NASDAQ USA Symbol : ORPH )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ORPH Other Details
Segment | EQ | |
Market Capital | 140894432.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
ORPH Address
ORPH Latest News
ORPH Business Profile
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Address: Ole MaalOees Vej 3, Copenhagen, Denmark, 2200
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service